Covance by Labcorp is a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 26,000 people worldwide, we provide comprehensive drug development solutions and are on a mission to advance health and power clear, confident decisions.
Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise.
Together with our clients, Covance by Labcorp supports the development of innovative, life-changing treatments.
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.0 billion in FY2020. Learn about Labcorp at www.Labcorp.com, or follow us on LinkedIn and Twitter @Labcorp.
Our mission is to improve health and improve lives.
Our vision is to be recognized by clients as:
- The undisputed leader in providing drug development services
- A trusted partner whose hallmarks are
- Great people
- High-quality data
- A proven track record of integrating and streamlining the development process
Our values are to strive for operational and service excellence through a relentless focus on People, Process and Clients.
|2015||LabCorp® (NYSE: LH) acquires Covance Inc., creating the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end solutions for drug and diagnostics development and commercialization.|
|2011||Takeda Pharmaceuticals International, Inc. chooses Covance as one of its strategic partners to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology.|
|2010||Covance signs landmark agreement with Sanofi-Aventis for a 10-year strategic R&D alliance and acquires their Porcheville, France and Alnwick, United Kingdom sites.|
Covance acquires Merck's Seattle-based Gene Expression Laboratory. Under the agreement, Merck has committed to a five-year $145 million contract to purchase genomic analysis services from Covance.
Covance acquires Swiss Pharma Contract, a clinical research company based in Basel, Switzerland.
Covance purchases minority equity stake in Caprion Proteomics, the leading provider of proteomics-based services to the pharmaceutical industry, to further enhance its biomarkers service offering to clients.
Covance makes CRO history with the most comprehensive drug development partnership in the industry. Covance acquires Lilly’s Greenfield, Indiana campus and executes a 10-year service agreement with Lilly.
In celebration of their 10-year anniversary, Covance announces our partnership with CARE to support the Covance-CARE Early Childhood Development (ECD) Initiative for Orphans and Vulnerable Children in Rwanda.
Covance opens Central Labs facility in Shanghai, China.
|2006||Covance announces acquisition of eight early phase clinical pharmacology sites of Radiant Research, Inc. Opens the largest toxicology expansion in Madison, Wisconsin.|
|2002||Covance acquires Virtual Central Labs, now known as Local Laboratory Services.|
Central STET laboratory opens in Singapore to serve fast-growing East Asian market.
Covance expands pharmaceutical analysis facility in Harrogate, U.K. and Phase I clinical research unit in Leeds, U.K.
|1998||Covance acquires the Berkeley (California) Antibody Company.|
|1997||Covance begins operations as an independent, publicly traded company on the New York Stock Exchange (NYSE) after our official spin-off from Corning Incorporated.|